
    
      A total of 24 eligible adult subjects will be randomized in a 3:1 randomization ratio into
      two blinded treatment groups in the three dose cohorts with matching placebo arm. The
      duration of the observation would be 5 days for each subject with a single SAP-001 dosing to
      evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of
      oral SAP-001 (once daily) in adults gout patients with hyperuricemia.
    
  